Plasma lipoprotein and platelet function after heparin injection: studies in normal fasted and postprandial and in type V hyperlipoproteinemic subjects.
The effect of heparin injection (50 IU/kg body weight) on plasma lipoprotein concentration and composition as well as on platelet aggregation and 14C-serotonin release was studied in normal fasted subjects, normal subjects 4 hr after a fatty meal (postprandial state), and in primary type V hyperlipoproteinemic patients. Heparin injection resulted in a reduction in plasma triglyceride, cholesterol, and phospholipids as well as in the inhibition of platelet function in either the presence or the absence of the plasma environment. Heparin injection resulted in catabolism of triglyceride-rich lipoproteins and increment of cholesterol and protein in the high-density lipoprotein (HDL) density range. In fasted normal subjects, very-low-density lipoprotein (VLDL) was reduced by 50%; in the postprandial state, both VLDL and chylomicrons decreased similarly; but in phenotype V hyperlipoproteinemia, only chylomicrons (but not VLDL) degraded. Heparin injection also caused increased electrophoretic mobility of plasma lipoprotein. Upon incubation of similar lipoprotein concentration, derived before and after heparin injection, with normal washed platelets, we found that in all the groups all the lipoproteins (except HDL) derived after heparin injection caused reduction in platelet activity. High-density lipoproteins derived after heparin injection, especially from type V hyperlipoproteinemic subjects, increased normal platelet activity, and this probably represents an effect of chylomicron remnant particles in the HDL density range. Our study thus demonstrates altered composition and concentration of plasma lipoprotein after heparin injection and may suggest the appearance of remnant particles with atherogenic properties.
D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D004435:Eating; D005215:Fasting; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D006954:Hyperlipoproteinemia Type V / Q000097:blood*; D007122:Immunoelectrophoresis; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D012016:Reference Values; D012701:Serotonin / Q000097:blood
D001053:Apolipoproteins; D008074:Lipoproteins; D012701:Serotonin; D006493:Heparin